These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 27566954)

  • 21. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
    Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
    BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
    Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
    [No Abstract]   [Full Text] [Related]  

  • 24. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
    Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
    EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
    Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
    Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
    Wang B; Li J; Sun M; Sun L; Zhang X
    IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional SNP in stem of mir-146a affects Her2 status and breast cancer survival.
    Meshkat M; Tanha HM; Naeini MM; Ghaedi K; Sanati MH; Meshkat M; Bagheri F
    Cancer Biomark; 2016 Jul; 17(2):213-22. PubMed ID: 27434289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
    Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
    Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
    Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
    Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
    Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
    Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
    Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
    Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
    Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
    Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
    Matsui D; Zaidi AH; Martin SA; Omstead AN; Kosovec JE; Huleihel L; Saldin LT; DiCarlo C; Silverman JF; Hoppo T; Finley GG; Badylak SF; Kelly RJ; Jobe BA
    Oncotarget; 2016 Dec; 7(49):81281-81291. PubMed ID: 27793030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker.
    Lei B; Zhang XY; Zhou JP; Mu GN; Li YW; Zhang YX; Pang D
    Tumour Biol; 2016 Nov; 37(11):14757-14764. PubMed ID: 27629143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.
    Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
    Int J Cancer; 2013 Apr; 132(7):1633-45. PubMed ID: 22987275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multiple breast cancer stem cell model to predict recurrence of T
    Qiu Y; Wang L; Zhong X; Li L; Chen F; Xiao L; Liu F; Fu B; Zheng H; Ye F; Bu H
    BMC Cancer; 2019 Jul; 19(1):729. PubMed ID: 31340763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study.
    Pece S; Disalvatore D; Tosoni D; Vecchi M; Confalonieri S; Bertalot G; Viale G; Colleoni M; Veronesi P; Galimberti V; Di Fiore PP
    EBioMedicine; 2019 Apr; 42():352-362. PubMed ID: 30846393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer.
    Bobowicz M; Skrzypski M; Czapiewski P; Marczyk M; Maciejewska A; Jankowski M; Szulgo-Paczkowska A; Zegarski W; Pawłowski R; Polańska J; Biernat W; Jaśkiewicz J; Jassem J
    Clin Exp Metastasis; 2016 Dec; 33(8):765-773. PubMed ID: 27485175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.